Contract analysis

I. Executive Summary On October 12, 2023, the Internal Revenue Service, Large Business & International Division, Northeast Transfer Pricing Practice, Examination Team LB&I-NE-TP-2022-00641 (the "Exam Team"), issued a Notice of Proposed Adjustment ("NOPA") for tax years 2017 through 2020. The NOPA proposes net adjustments of $380.4 million to PPC's transfer pricing positions involving its Irish intellectual-property-h

II. Background A. PPC's Transfer Pricing Structure Penterra Pharmaceuticals Corp. ("PPC") is a publicly traded specialty pharmaceutical and biotechnology company incorporated in Delaware and listed on the Nasdaq Global Select Market under the ticker symbol "PPCA" (Employer Identification Number 22-3741856). PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. For fiscal year 2020

III. Summary of IRS Notice of Proposed Adjustment (October 12, 2023) On October 12, 2023, the Exam Team issued the NOPA proposing aggregate net adjustments of $380.4 million to PPC's taxable income for tax years 2017 through 2020. The NOPA adjustments are organized into three principal categories, each of which is discussed below. A 30-Day Letter was subsequently issued on November 8, 2023, affording PPC the opportun

IV. ASC 740-10 (FIN 48) Framework A. Two-Step Analysis The analysis of uncertain tax positions under ASC 740-10 (formerly FIN 48) involves a two-step process that governs both whether a tax benefit is recognized in the financial statements and, if so, the amount of benefit that is recognized. Step 1 — Recognition. Under ASC 740-10-25-6, a tax position is recognized in the financial statements only if it is "more like

V. Updated Recognition Analysis (Step 1) — Position-by-Position A. CSA Cost-Sharing Ratios PPC's Position. PPC's cost-sharing percentages of 38.2% (2017), 39.6% (2018), 41.1% (2019), and 42.7% (2020) were determined based on projections of PBI's reasonably anticipated benefits relative to PPC's reasonably anticipated benefits from the intangible property developed under the CSA. These projections were prepared in acc

VI. Updated Measurement Analysis (Step 2) — Probability-Weighted Outcomes A. Methodology Having determined that PPC's transfer pricing positions meet the more-likely-than-not recognition threshold, the analysis proceeds to the measurement step under ASC 740-10-30-7. The measurement step requires determining the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with

1. CSA Cost-Sharing Adjustments ($235.01M Proposed) C&H has assessed the range of possible outcomes for the CSA cost-sharing adjustments as follows: The full sustain outcome reflects the possibility that the IRS's proposed adjustments are entirely rejected at Appeals or in litigation. The minor adjustment outcome, which carries the highest individual probability, reflects the most likely settlement scenario in which

2. Royalty Rate Adjustments ($188.04M Proposed) C&H has assessed the range of possible outcomes for the royalty rate adjustments as follows: The full sustain outcome carries a somewhat higher probability for the royalty rate issue than for the CSA issue, reflecting the strength of PPC's CUT analysis and the fact that PPC's 4.5% rate is at the median of the comparable data. The minor adjustment outcome reflects a sett

3. Economic Substance / PBI Recharacterization The IRS's economic substance challenge to PBI does not represent a standalone numerical adjustment but rather serves as the theoretical underpinning for both the CSA and royalty adjustments. If the IRS were to prevail fully on its economic substance argument, it could support a complete recharacterization of the intercompany arrangements that would effectively eliminate

4. Correlative Offset In any settlement scenario, a correlative offset would apply to avoid double-counting between the CSA and royalty adjustments, consistent with the Exam Team's recognition of a ($42.65 million) offset in the NOPA. The magnitude of the correlative offset would vary depending on the specific settlement terms but would serve to reduce the total adjustment below the sum of the individual CSA and roya

VII. Impact of NOPA on Reserve Adequacy A. Why the NOPA Does Not Require a Reserve Increase While the issuance of the NOPA is a significant event in the examination process, C&H has concluded that it does not warrant an increase in PPC's FIN 48 reserve for the following reasons: The NOPA Represents the IRS's Maximum Opening Position. As a matter of standard IRS examination practice, the NOPA reflects the Exam Team's

VIII. Comparison to Initial September 2022 Analysis C&H's initial FIN 48 analysis, dated September 2022, established the $62.4 million uncertain tax position reserve based on C&H's estimated probability of an IRS challenge to PPC's CSA and royalty positions, the likely magnitude of any such challenge, and the probability-weighted range of outcomes upon ultimate resolution. The September 2022 analysis was prepared at

IX. Financial Statement Disclosure Considerations A. SEC Reporting Obligations PPC, as a publicly traded company listed on the Nasdaq Global Select Market (ticker: PPCA), is subject to the reporting requirements of the Securities Exchange Act of 1934, including the obligation to disclose material contingent liabilities in its annual report on Form 10-K and quarterly reports on Form 10-Q. The proposed $380.4 million a